Gaucher Disease-Pipeline Review H1 2017
ReportsWeb.com has announced the addition of the “Gaucher Disease-Pipeline Review H1 2017” this report provides an overview of the Gaucher Disease (Genetic Disorders) pipeline landscape.
(EMAILWIRE.COM, June 20, 2017 ) Gaucher disease is a rare genetic disorder occurs due to lacks an enzyme called glucocerebrosidase. Symptoms include cognitive impairment, enlarged spleen, severe swelling, lung disease, fatigue and seizures. Treatment includes enzyme replacement therapy.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Gaucher Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gaucher Disease (Genetic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gaucher Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gaucher Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 11 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 5 molecules, respectively.
Gaucher Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/gaucher-disease-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gaucher Disease (Genetic Disorders) .
- The pipeline guide reviews pipeline therapeutics for Gaucher Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gaucher Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gaucher Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gaucher Disease (Genetic Disorders)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001834393/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gaucher Disease (Genetic Disorders) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gaucher Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Actelion Ltd
Genzyme Corp
greenovation Biotech GmbH
JCR Pharmaceuticals Co Ltd
Lixte Biotechnology Holdings Inc
Neuraltus Pharmaceuticals Inc
Orphazyme ApS
Pharming Group NV
Protalix BioTherapeutics Inc
Shire Plc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001834393/discount
Table of Contents
Number of Products under Development for Gaucher Disease, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Gaucher Disease - Pipeline by Actelion Ltd, H1 2017
Gaucher Disease - Pipeline by Genzyme Corp, H1 2017
Gaucher Disease - Pipeline by greenovation Biotech GmbH, H1 2017
Gaucher Disease - Pipeline by JCR Pharmaceuticals Co Ltd, H1 2017
Gaucher Disease - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
Gaucher Disease - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2017
Gaucher Disease - Pipeline by Orphazyme ApS, H1 2017
Gaucher Disease - Pipeline by Pharming Group NV, H1 2017
Gaucher Disease - Pipeline by Protalix BioTherapeutics Inc, H1 2017
Gaucher Disease - Pipeline by Shire Plc, H1 2017
Gaucher Disease - Dormant Projects, H1 2017
Gaucher Disease - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001834393/buy/2000
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Gaucher Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gaucher Disease (Genetic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gaucher Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gaucher Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 11 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 5 molecules, respectively.
Gaucher Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/gaucher-disease-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gaucher Disease (Genetic Disorders) .
- The pipeline guide reviews pipeline therapeutics for Gaucher Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gaucher Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gaucher Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gaucher Disease (Genetic Disorders)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001834393/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gaucher Disease (Genetic Disorders) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gaucher Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Actelion Ltd
Genzyme Corp
greenovation Biotech GmbH
JCR Pharmaceuticals Co Ltd
Lixte Biotechnology Holdings Inc
Neuraltus Pharmaceuticals Inc
Orphazyme ApS
Pharming Group NV
Protalix BioTherapeutics Inc
Shire Plc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001834393/discount
Table of Contents
Number of Products under Development for Gaucher Disease, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Gaucher Disease - Pipeline by Actelion Ltd, H1 2017
Gaucher Disease - Pipeline by Genzyme Corp, H1 2017
Gaucher Disease - Pipeline by greenovation Biotech GmbH, H1 2017
Gaucher Disease - Pipeline by JCR Pharmaceuticals Co Ltd, H1 2017
Gaucher Disease - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
Gaucher Disease - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2017
Gaucher Disease - Pipeline by Orphazyme ApS, H1 2017
Gaucher Disease - Pipeline by Pharming Group NV, H1 2017
Gaucher Disease - Pipeline by Protalix BioTherapeutics Inc, H1 2017
Gaucher Disease - Pipeline by Shire Plc, H1 2017
Gaucher Disease - Dormant Projects, H1 2017
Gaucher Disease - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001834393/buy/2000
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results